172 related articles for article (PubMed ID: 26341695)
61. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
[TBL] [Abstract][Full Text] [Related]
62. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
[TBL] [Abstract][Full Text] [Related]
63. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
64. Production of glass microspheres comprising 90Y and (177)Lu for treating of hepatic tumors with SPECT imaging capabilities.
Poorbaygi H; Reza Aghamiri SM; Sheibani S; Kamali-Asl A; Mohagheghpoor E
Appl Radiat Isot; 2011 Oct; 69(10):1407-14. PubMed ID: 21723135
[TBL] [Abstract][Full Text] [Related]
65. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
[TBL] [Abstract][Full Text] [Related]
66. Self-Monitoring and Self-Delivery of Photosensitizer-Doped Nanoparticles for Highly Effective Combination Cancer Therapy in Vitro and in Vivo.
Zhang J; Liang YC; Lin X; Zhu X; Yan L; Li S; Yang X; Zhu G; Rogach AL; Yu PK; Shi P; Tu LC; Chang CC; Zhang X; Chen X; Zhang W; Lee CS
ACS Nano; 2015 Oct; 9(10):9741-56. PubMed ID: 26390118
[TBL] [Abstract][Full Text] [Related]
67. Calcium carbonate carriers for combined chemo- and radionuclide therapy of metastatic lung cancer.
Timin AS; Postovalova AS; Karpov TE; Antuganov D; Bukreeva AS; Akhmetova DR; Rogova AS; Muslimov AR; Rodimova SA; Kuznetsova DS; Zyuzin MV
J Control Release; 2022 Apr; 344():1-11. PubMed ID: 35181413
[TBL] [Abstract][Full Text] [Related]
68. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
Chakraborty S; Sarma HD; Vimalnath KV; Pillai MR
Nucl Med Biol; 2013 Oct; 40(7):946-54. PubMed ID: 23850487
[TBL] [Abstract][Full Text] [Related]
69. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.
Schoffelen R; van der Graaf WT; Sharkey RM; Franssen GM; McBride WJ; Chang CH; Bos DL; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2012 Dec; 53(12):1926-32. PubMed ID: 23081995
[TBL] [Abstract][Full Text] [Related]
70. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
Beaino W; Nedrow JR; Anderson CJ
Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
[TBL] [Abstract][Full Text] [Related]
71. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
Jiang L; Miao Z; Liu H; Ren G; Bao A; Cutler CS; Shi H; Cheng Z
Nucl Med Commun; 2013 Sep; 34(9):909-14. PubMed ID: 23708872
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of cobalt-labeled octreotide analogs for molecular imaging and auger electron-based radionuclide therapy.
Thisgaard H; Olsen BB; Dam JH; Bollen P; Mollenhauer J; Høilund-Carlsen PF
J Nucl Med; 2014 Aug; 55(8):1311-6. PubMed ID: 24876207
[TBL] [Abstract][Full Text] [Related]
73. Preparation, evaluation, and first clinical use of 177Lu-labeled hydroxyapatite (HA) particles in the treatment of rheumatoid arthritis: utility of cold kits for convenient dose formulation at hospital radiopharmacy.
Chakraborty S; Vimalnath KV; Rajeswari A; Shinto A; Sarma HD; Kamaleshwaran K; Thirumalaisamy P; Dash A
J Labelled Comp Radiopharm; 2014 Jun; 57(7):453-62. PubMed ID: 24966157
[TBL] [Abstract][Full Text] [Related]
74. Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts.
Abbas N; Bruland ØS; Brevik EM; Dahle J
Nucl Med Commun; 2012 Aug; 33(8):838-47. PubMed ID: 22643311
[TBL] [Abstract][Full Text] [Related]
75. Radiolabeling of lipid-based nanoparticles for diagnostics and therapeutic applications: a comparison using different radiometals.
Helbok A; Decristoforo C; Dobrozemsky G; Rangger C; Diederen E; Stark B; Prassl R; von Guggenberg E
J Liposome Res; 2010 Sep; 20(3):219-27. PubMed ID: 19863193
[TBL] [Abstract][Full Text] [Related]
76. A Theranostic Cellulose Nanocrystal-Based Drug Delivery System with Enhanced Retention in Pulmonary Metastasis of Melanoma.
Imlimthan S; Khng YC; Keinänen O; Zhang W; Airaksinen AJ; Kostiainen MA; Zeglis BM; Santos HA; Sarparanta M
Small; 2021 May; 17(18):e2007705. PubMed ID: 33738957
[TBL] [Abstract][Full Text] [Related]
77. Molecular imaging in drug development: Update and challenges for radiolabeled antibodies and nanotechnology.
Colombo I; Overchuk M; Chen J; Reilly RM; Zheng G; Lheureux S
Methods; 2017 Nov; 130():23-35. PubMed ID: 28743635
[TBL] [Abstract][Full Text] [Related]
78. Theranostic Nanoseeds for Efficacious Internal Radiation Therapy of Unresectable Solid Tumors.
Moeendarbari S; Tekade R; Mulgaonkar A; Christensen P; Ramezani S; Hassan G; Jiang R; Öz OK; Hao Y; Sun X
Sci Rep; 2016 Feb; 6():20614. PubMed ID: 26852805
[TBL] [Abstract][Full Text] [Related]
79. Tumor-selective catalytic nanomedicine by nanocatalyst delivery.
Huo M; Wang L; Chen Y; Shi J
Nat Commun; 2017 Aug; 8(1):357. PubMed ID: 28842577
[TBL] [Abstract][Full Text] [Related]
80. Towards understanding the distribution and tumor targeting of sericin regulated spherical calcium phosphate nanoparticles.
Zhao R; Ren X; Xie C; Kong X
Microsc Res Tech; 2017 Mar; 80(3):321-330. PubMed ID: 27859881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
